RhumbLine Advisers
CBPO

RhumbLine Advisers’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

RhumbLine Advisers’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,400
Closed -$347K – 3083
2020
Q2 		$347K Buy
+3,400
New +$364K ﹤0.01% 2508

Other funds holding CBPO

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
MCP
Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capstone Investment Advisors
Capstone Investment Advisors New York $57.4B AUM 26.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

RhumbLine Advisers's CBPO Position: Q3 2020 in Review

RhumbLine Advisers sold out of China Biologic Products Holdings, Inc. (CBPO) in Q3 2020, closing a stake of 3,400 shares — an estimated $347K sold.

RhumbLine Advisers first reported a position in CBPO in Q2 2020 and held it in 1 quarter. The position peaked at $347K in Q2 2020. 87 funds tracked by Wall St. Rank hold CBPO as of Q3 2020.

  • RhumbLine Advisers reported no remaining China Biologic Products Holdings, Inc. position as of Q3 2020 after selling out during the quarter.
  • RhumbLine Advisers sold 3,400 China Biologic Products Holdings, Inc. shares in Q3 2020, an estimated $347K.
  • RhumbLine Advisers first reported a position in China Biologic Products Holdings, Inc. in Q2 2020 and held it in 1 quarter.
  • RhumbLine Advisers's China Biologic Products Holdings, Inc. position peaked at $347K in Q2 2020.
  • 87 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q3 2020.

Based on RhumbLine Advisers's 13F filing for Q3 2020, filed 12 Nov 2020.